Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Collegium Pharmaceutical Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Collegium Pharmaceutical Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Inventory
$38m
CAGR 3-Years
30%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Inventory
$12.6B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
4%
Bristol-Myers Squibb Co
NYSE:BMY
Inventory
$3.3B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Inventory
$11.4B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Inventory
$6.2B
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Inventory
$7.5B
CAGR 3-Years
24%
CAGR 5-Years
19%
CAGR 10-Years
10%
No Stocks Found

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Collegium Pharmaceutical Inc's Inventory?
Inventory
38m USD

Based on the financial report for Sep 30, 2024, Collegium Pharmaceutical Inc's Inventory amounts to 38m USD.

What is Collegium Pharmaceutical Inc's Inventory growth rate?
Inventory CAGR 5Y
34%

Over the last year, the Inventory growth was 12%. The average annual Inventory growth rates for Collegium Pharmaceutical Inc have been 30% over the past three years , 34% over the past five years .

Back to Top